Seek Labs and NAMRU EURAFCENT Enter CRADA to Evaluate Field-Deployable Diagnostics for Infectious Diseases
SALT LAKE CITY, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Seek Labs, a private TechBio company building programmable platforms
Press Release Disclaimer: This is a press release distributed through the XPR Media network. It has not been independently verified by our newsroom.
SALT LAKE CITY, Aug. 24, 2026 (GLOBE NEWSWIRE) — Seek Labs, a private TechBio company building programmable platforms to decode, program, and resolve diseases, today announced a Cooperative Research and Development Agreement (CRADA) with the Naval Medical Research Unit (NAMRU) EURAFCENT, part of Navy Medicine Research & Development that is focused on infectious disease threats affecting military personnel, to evaluate SeekIt™, the company’s instrument-free molecular diagnostic platform. SeekIt includes a field kit and single-use device for detecting infectious diseases in forward-deployed, austere, and resource-constrained settings.
“SeekIt is designed around a single principle: molecular diagnostics should go where the disease is, not the other way around,” said Kim Wirthlin, Chief Strategy Officer for Seek Labs. “SeekIt puts a full laboratory-grade molecular test—including extraction, amplification, and detection—into a handheld, instrument-free kit of discrete, individually packaged components. It is designed for forward-deployed medical teams, expeditionary operations, shipboard use, and outbreak surveillance in austere environments without the need for electricity, instruments, or cold chain.”
Under the CRADA, Seek Labs and NAMRU EURAFCENT will evaluate the SeekIt™ field kit for usability and operational integration, pairing Seek Labs’ test development with NAMRU EURAFCENT’s biosurveillance, laboratory testing coordination, and definition of military use cases. The work is expected to inform future R&D pathways and additional areas of collaboration.
“The SeekIt platform has the potential to revolutionize how we approach bio surveillance,” said Capt. Michael Prouty, commanding officer of NAMRU EURAFCENT, in a recent official Navy release. “In the remote and often austere settings where our forces operate, having a rapid, reliable, and field-deployable diagnostic capability is not just an advantage, it is a necessity for maintaining mission readiness and operational effectiveness.”
By integrating the SeekIt™ field kit with NAMRU EURAFCENT’s biosurveillance and operational research expertise, the collaboration aims to deliver scalable, field-ready solutions that help NAMRU EURAFCENT protect warfighter health and sustain operational effectiveness in demanding environments worldwide.
About Seek Labs
Every disease has a sequence. Seek Labs is a TechBio company building systems to decode, program, and resolve disease. At the core of its platform is an AI-powered intelligence layer that analyzes and translates sequences into actionable data, informing two deployment layers: Sequence Ablation Therapeutics (SAT) and molecular detection. Together, these systems form a continuous loop in which genomic data is decoded, translated into therapeutic and diagnostic outputs, and refined through real-world deployment.
Headquartered in Salt Lake City, Seek Labs is a proud member of BioHive, Utah’s collaborative life sciences ecosystem. Together with its partners, Seek Labs is building faster, smarter solutions for urgent health challenges.
About NAMRU EURAFCENT
NAMRU EURAFCENT, part of Navy Medicine Research & Development, conducts research, surveillance and studies of vaccines, therapeutic agents, diagnostic assays and vector control measures in the EUCOM, AFRICOM and CENTCOM Areas of Responsibility to better prevent and treat infectious diseases in support of Navy, Marine Corps and joint U.S. warfighter health, readiness and lethality.
Media Contact: Bridget Baldwin, Director of Communications communications@seeklabs.com
Media gallery
